EGFR and neoplasm: In addition, 1G EGFR-TKIs involved gefitinib, erlotinib and icotinib, and EGFR alterations was confirmed by different detection methods, including ARMS-PCR or NGS based on specimens of tumor tissue or plasma samples, and selection bias was inevitable.